(NYSE: DNA) Ginkgo Bioworks Holdings's forecast annual revenue growth rate of 21.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Ginkgo Bioworks Holdings's revenue in 2024 is $208,697,000.On average, 2 Wall Street analysts forecast DNA's revenue for 2024 to be $387,369,463,156, with the lowest DNA revenue forecast at $384,762,366,432, and the highest DNA revenue forecast at $389,976,559,881. On average, 3 Wall Street analysts forecast DNA's revenue for 2025 to be $616,557,368,150, with the lowest DNA revenue forecast at $482,058,597,024, and the highest DNA revenue forecast at $880,752,014,654.
In 2026, DNA is forecast to generate $828,811,306,464 in revenue, with the lowest revenue forecast at $662,105,271,734 and the highest revenue forecast at $995,517,341,194.